LONDON--()--Michael Fort has been appointed a non-executive director of Interface Clinical Services, the UK’s leading provider of clinical Improvement programmes for the NHS and pharma.
“I am delighted to welcome Michael to the board. Having worked with him for more than twenty years I know that his expertise in the building of successful healthcare companies will help to accelerate the development and growth of Interface Clinical Services.”
Michael, who previously built Synexus into the world’s largest multinational company entirely focussed on the recruitment and running of clinical trials, believes that interface Clinical Services, already the leader in its space has a huge opportunity to grow in a fragmented but very large marketplace.
Mike Drakard founder and CEO of Interface commented, “I am delighted to welcome Michael to the board. Having worked with him for more than twenty years I know that his expertise in the building of successful healthcare companies will help to accelerate the development and growth of Interface Clinical Services.”
Michael Fort has also invested in the business.
In 2010 Michael was BVCA Portfolio Company CEO of the Year and the Ernst & Young Turnaround Entrepreneur of the Year - North & Midlands.
About Interface Clinical Services
Over the last few years Interface has grown from a small organisation supporting medicine management projects on behalf of PCTs to one of the largest and most experienced suppliers of clinical services in the UK.
Through a large team of highly trained clinical pharmacists, using both standard and bespoke software, Interface has become one of the most successful support organisations within primary care, contracting with NHS trusts across the UK. They have also developed a range of specialist projects delivering innovative solutions to often complex clinical issues, new service pathways and increased efficiency for primary care clients and for pharma.
This extensive knowledge base and expertise puts the company in an excellent position to support CCGs in developing new clinical services for their patient populations.